Trulieve Cannabis Corp. — Form 8-K
Filed August 7, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 72/100
What the filing says
Trulieve Cannabis completed NYSE listing on June 10, 2026 (ticker TRLV) after deconsolidating mixed-use Harvest operations on June 3, 2026 to a third-party investor (retaining 90% economic interest). Q2 2026 reported revenue $271M (medical-only: $222M) with 60% gross margin; GAAP net loss $406M (includes $403M Harvest deconsolidation charge); adjusted net income $20M; adjusted EBITDA $98M (36% margin); cash position $325M; operates 207 dispensaries and 3.5M sq ft production capacity in medical-only states post-restructuring.
Why this rating
NYSE listing is landmark regulatory/capital markets event; Harvest deconsolidation ($403M charge) is significant restructuring. Revenue ~$271M is 45% of $600M market cap—core operations healthy. Adjusted EBITDA $98M and 36% margin show underlying profitability. Medical rescheduling removes 280E tax burden (upside). Growth catalysts in Georgia, Texas, pharmacy distribution credible. However, Q2 revenue down 10% YoY; adjusted metrics mask large one-time charges. Net listing + tax relief positive, but execution risk remains.
See more from August 7, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.